Department of Medicine, New York Presbyterian/Weill Cornell Medical Center, 505 E. 70th Street, Suite 450, New York, NY 10021, USA.
Curr Atheroscler Rep. 2012 Feb;14(1):60-9. doi: 10.1007/s11883-011-0221-0.
Overweight and obesity are now recognized as leading causes of diseases such as type 2 diabetes, hypertension, hyperlipidemia, and ultimately, cardiovascular disease. Despite the serious consequences, roughly two thirds of Americans are presently classified as overweight, and about one third are classified as obese. Weight loss via lifestyle modification and pharmacotherapy can promote improvement in many of these obesity-related conditions. This review addresses recent advances in pharmacotherapy for the management of obesity and obesity-related co-morbidities, with a focus on the management of obesity specifically in individuals with type 2 diabetes. Emphasis is also placed on a proposed paradigm shift from the glucose-centric to the weight-centric management of type 2 diabetes mellitus.
超重和肥胖现在被认为是 2 型糖尿病、高血压、高血脂等疾病的主要原因，最终还会导致心血管疾病。尽管后果严重，但目前大约有三分之二的美国人超重，约三分之一的人肥胖。通过生活方式改变和药物治疗减肥，可以促进许多与肥胖相关的疾病的改善。这篇综述讨论了肥胖症和肥胖相关合并症的药物治疗的最新进展，重点是专门针对 2 型糖尿病患者的肥胖症管理。此外，还强调了从以血糖为中心到以体重为中心的 2 型糖尿病管理模式的转变。
